1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Type 1 Diabetes (Juvenile Diabetes) - Drugs In Development, 2022, provides an overview of the Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Type 1 diabetes (T1D) is an autoimmune disease in which a pancreas stops producing insulin, a hormone that enables people to get energy from food. It occurs when the body's immune system attacks and destroys the insulin-producing cells in the pancreas, called beta cells. Risk factors of type 1 diabetes include genetics and family history, diseases of the pancreas and infection or illness. The signs and symptoms of type 1 diabetes include increased thirst and frequent urination, extreme hunger, weight loss, fatigue, irritability or unusual behavior.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Type 1 Diabetes (Juvenile Diabetes) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Type 1 Diabetes (Juvenile Diabetes) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 2, 14, 37, 38, 1, 3, 151, 40 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 2, 3, 1, 34 and 5 molecules, respectively.
Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Type 1 Diabetes (Juvenile Diabetes) - Overview
- Type 1 Diabetes (Juvenile Diabetes) - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Type 1 Diabetes (Juvenile Diabetes) - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Type 1 Diabetes (Juvenile Diabetes) - Companies Involved in Therapeutics Development
- Type 1 Diabetes (Juvenile Diabetes) - Drug Profiles
- Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects
- Type 1 Diabetes (Juvenile Diabetes) - Discontinued Products
- Type 1 Diabetes (Juvenile Diabetes) - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes), 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects, 2022
- Type 1 Diabetes (Juvenile Diabetes) - Discontinued Products, 2022
- Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes), 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abata Therapeutics
- Aditxt Inc
- Adocia SAS
- Aerami Therapeutics Inc
- Ahead Therapeutics SL
- Akston Biosciences Corp
- Algiax Pharmaceuticals GmbH
- Allele Biotechnology and Pharmaceuticals Inc
- Alpine Immune Sciences Inc
- Altheia Science SRL
- ALTuCELL
- Amarna Therapeutics BV
- Amide Technologies Inc
- AmideBio, LLC
- Amogen Pharma Pvt Ltd
- Amytrx Therapeutics Inc
- Anokion SA
- Aphios Corp
- Apodemus AB
- APT Therapeutics Inc
- Aptamer Sciences Inc
- Arecor Therapeutics Plc
- Ariddad Therapeutics SL
- Artery Therapeutics Inc
- Asake Biotechnology LLC
- AskGene Pharma Inc
- AstraZeneca Plc
- Asylia Therapeutics Inc
- AVM Biotechnology LLC
- Avotres Inc
- Axxam SpA
- Beijing Advaccine Biotechnology Company Ltd
- Beta-Cell NV
- Biocon Ltd
- Biogenomics Ltd
- BioLingus AG
- Biomea Fusion Inc
- Bioorg3.14 LLC
- BioTherapeutics Inc
- Biozeus Pharmaceutical SA
- BirchBioMed Inc
- Bol Pharma
- Bopin (Shanghai) Biomedical Technology Co Ltd
- Bristol-Myers Squibb Co
- BTB Pharma AB
- CAR-T (Shanghai) Biotechnology Co Ltd
- Carlina Technologies SAS
- Cell Source Inc
- CellTrans Inc
- Chongqing Chenan BioPharm Co Ltd
- Code Biotherapeutics Inc
- Coegin Pharma AS
- Compugen Ltd
- Cour Pharmaceuticals Development Co Inc
- Creative Medical Technology Holdings Inc
- CRISPR Therapeutics AG
- Cue Biopharma Inc
- Daewoong Pharmaceutical Co Ltd
- Dendright Pty Ltd
- Diabetology (Products) Ltd
- Diamyd Medical AB
- Diasome Pharmaceuticals Inc
- DiaVacs Inc
- Dompe Farmaceutici SpA
- Dualogics Corp
- Eli Lilly and Co
- Endsulin Inc
- Ensol Biosciences Inc
- Enthera Srl
- EpiVax Inc
- Evotec SE
- FasCure Therapeutics LLC
- Felicitex Therapeutics Inc
- Foshan Rexie Biotechnology Co Ltd
- Fresh Tracks Therapeutics Inc
- Gan & Lee Pharmaceuticals Co Ltd
- Generex Biotechnology Corp
- Genprex Inc
- GentiBio Inc
- Geropharm
- Great Bay Bio Holdings Ltd
- Gubra ApS
- Gwoxi Stem Cell Applied Technology Co Ltd
- Hanmi Pharmaceuticals Co Ltd
- Housey Pharmaceutical Research Laboratories LLC
- Hua Medicine Shanghai Ltd
- Iltoo Pharma
- Imagine Pharma LLC
- ImCyse SA
- Immunocore Holdings Plc
- ImmunoMolecular Therapeutics LLC
- Immunwork Inc
- ImmusanT Inc
- Imstem Biotechnology Inc
- Innovimmune Biotherapeutics Inc
- Inspira Therapeutics Inc
- Intarcia Therapeutics Inc
- Inversago Pharma Inc
- iTolerance Inc
- Jaguar Gene Therapy LLC
- Jiangsu Hengrui Medicine Co Ltd
- Jiangsu Lianhuan Pharmaceutical Co Ltd
- JN Biosciences LLC
- Johnson & Johnson
- Kadimastem Ltd
- Kamada Pharmaceuticals
- Kiniksa Pharmaceuticals Ltd
- Kriya Therapeutics Inc
- Kunming Yinnuo Medical Technology Co. Ltd.
- L2 Diagnostics LLC
- Landos Biopharma Inc
- Lannett Co Inc
- Larix Bioscience LLC
- Laverock Therapeutics Ltd
- Lexicon Pharmaceuticals Inc
- Likarda LLC
- MannKind Corp
- Maruho Co Ltd
- Medytox Inc
- Melior Pharmaceuticals I Inc
- Mercia Pharma Inc
- Merck & Co Inc
- MidaSol Therapeutics LP
- Moderna Inc
- Neovacs SA
- Neurodon LLC
- Neuromagen Pharma Ltd
- NexImmune Inc
- NextCell Pharma AB
- NightHawk Biosciences Inc
- Novartis AG
- Novo Nordisk AS
- OneVax LLC
- Op-T-Mune Inc
- Oramed Pharmaceuticals Inc
- Orgenesis Inc
- Orion BioScience Inc
- Orizuru Therapeutics Inc
- Otsuka Pharmaceutical Co Ltd
- Panbela Therapeutics Inc
- Pancryos AS
- Panorama Researchama Research
- Paras Biopharmaceuticals Finland Oy
- Parvus Therapeutics Inc
- Pfizer Inc
- Phaim Pharma Ltd
- PharmaCyte Biotech Inc
- Pharmasum Therapeutics AS
- PolTREG SA
- Polus Inc
- Precigen Inc
- Prometheon Pharma LLC
- Protheragen Inc
- Protokinetix Inc
- Protomer Technologies Inc
- Provention Bio Inc
- Purzer Pharmaceutical Co Ltd
- Reata Pharmaceuticals Inc
- Regenerative Medical Solutions Inc
- REGiMMUNE Corp
- Remd Biotherapeutics Inc
- Remedium Bio Inc
- reMYND NV
- ReNeuron Group Plc
- Renova Therapeutics Inc
- Repertoire Immune Medicines Inc
- RosVivo Therapeutics Inc
- Rubius Therapeutics Inc
- SAB Biotherapeutics Inc
- Sahane Biotech Inc
- Sana Biotechnology Inc
- Sanofi
- Sensulin LLC
- Seraxis Inc
- Serpin Pharma LLC
- Shanghai Innogen Pharmaceutical Technology Co Ltd
- Sihuan Pharmaceutical Holdings Group Ltd
- Slate Bio Inc
- Sonoma Biotherapeutics Inc
- SQZ Biotechnologies Co
- Stelis Biopharma Ltd
- Suntec Medical (Taiwan) Inc
- Surrozen Inc
- SymbioCellTech LLC
- Tetragenetics Inc
- Theertha Biopharma Pvt Ltd
- TherapyX Inc
- Thermalin Inc
- Throne Biotechnologies Inc
- Tiziana Life Sciences Plc
- Trailhead Biosystems Inc
- Transgene Biotek Ltd
- TwotoBiotech Ltd
- Unicyte AG
- Valin Technologies Ltd
- Vanilloid Genetics Inc
- Ventria Bioscience Inc
- Veralox Therapeutics Inc
- Vertex Pharmaceuticals Inc
- ViaCyte Inc
- ViCapsys Inc
- Virtici LLC
- vTv Therapeutics Inc
- Wockhardt Ltd
- Xeris Biopharma Holdings Inc
- XL-protein GmbH
- XOMA Corp
- Yichang Hec Changjiang Pharmaceutical Co Ltd
- Youngene Therapeutics Co Ltd
- Zucara Therapeutics Inc
